Weiss Asset Management LP Makes New Investment in BioCryst Pharmaceuticals, Inc. $BCRX

Weiss Asset Management LP purchased a new stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) during the first quarter, HoldingsChannel.com reports. The fund purchased 82,100 shares of the biotechnology company’s stock, valued at approximately $782,000.

Several other large investors also recently made changes to their positions in the stock. Larson Financial Group LLC raised its holdings in shares of BioCryst Pharmaceuticals by 1,188.0% during the fourth quarter. Larson Financial Group LLC now owns 3,542 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 3,267 shares during the period. Focus Partners Wealth acquired a new position in BioCryst Pharmaceuticals in the 3rd quarter worth $77,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in BioCryst Pharmaceuticals by 26.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 2,115 shares during the period. Hilltop Holdings Inc. bought a new position in BioCryst Pharmaceuticals during the 1st quarter worth about $98,000. Finally, Envestnet Portfolio Solutions Inc. bought a new position in BioCryst Pharmaceuticals during the 4th quarter worth about $81,000. Institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Price Performance

Shares of NASDAQ:BCRX opened at $9.58 on Tuesday. The company’s 50-day moving average price is $9.23 and its two-hundred day moving average price is $8.59. BioCryst Pharmaceuticals, Inc. has a one year low of $6.00 and a one year high of $11.22. The stock has a market capitalization of $2.43 billion, a PE ratio of -5.38 and a beta of 0.55.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported ($2.98) earnings per share for the quarter, missing the consensus estimate of $0.06 by ($3.04). The company had revenue of $156.41 million during the quarter, compared to the consensus estimate of $151.12 million. BioCryst Pharmaceuticals had a negative net margin of 51.71% and a negative return on equity of 76.36%. BioCryst Pharmaceuticals’s revenue was up 7.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.20 EPS. On average, analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -2.58 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

BCRX has been the topic of a number of research reports. Royal Bank Of Canada boosted their price target on BioCryst Pharmaceuticals from $13.00 to $14.00 and gave the company an “outperform” rating in a report on Tuesday, July 7th. JPMorgan Chase & Co. assumed coverage on BioCryst Pharmaceuticals in a report on Monday, July 13th. They set a “neutral” rating and a $12.00 price objective for the company. Weiss Ratings reissued a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a research report on Monday, June 1st. HC Wainwright restated a “buy” rating and issued a $32.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, June 30th. Finally, Wedbush reduced their price target on BioCryst Pharmaceuticals from $22.00 to $21.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Eight equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $20.80.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.